| Symbol |
LRRK2 |
| Full Name |
Leucine Rich Repeat Kinase 2 |
| Chromosome |
12q12 |
| NCBI Gene |
120892 |
| Ensembl |
ENSG00000188906 |
| OMIM |
609007 |
| UniProt |
Q5S007 |
| Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease) |
| Expression |
Striatum, Cerebral cortex, Kidney, Lungs |
| G2019S, R1441C/G/H, Y1699C, I2020T |
Lrrk2 — Leucine Rich Repeat Kinase 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
LRRK2 (Leucine-Rich Repeat Kinase 2), also known as dardarin, is a large multi-domain protein kinase encoded by the LRRK2 gene on chromosome 12q12. It is one of the most common genetic causes of Parkinson's disease (PD), with pathogenic mutations accounting for approximately 5-10% of familial PD cases and 1-3% of sporadic PD cases. The LRRK2 protein is a member of the ROCO family of Ras-of-Complex (ROC) proteins and possesses both kinase and GTPase activity.
The discovery of LRRK2 mutations as a cause of PARK8-linked Parkinson's disease in 2004 marked a major breakthrough in understanding the genetics of PD and has led to extensive research into its function and therapeutic targeting.
LRRK2 is a 2527-amino acid protein with a complex multi-domain architecture:
¶ N-Terminal Domains
- Armadillo repeats (residues 100-300): Protein-protein interactions
- Ankyrin repeats (residues 400-600): Scaffold for signaling complexes
- LEPR/LRR repeats (residues 1000-1300): Protein binding, possibly ligand recognition
¶ Central Domain
- Kinase domain (MAPKKK domain, residues 1900-2100): Catalytic kinase activity
- Activation loop: Contains the critical G2019S mutation site
¶ C-Terminal Domain
- ROC domain (Ras of complex proteins, residues 1400-1500): GTPase activity
- COR domain (C-terminal of ROC, residues 1500-1800): Dimerization, regulation
- WD40 repeat (residues 2200-2400): Protein-protein interactions
The kinase domain shares homology with the MAPKKK family and is the primary therapeutic target for LRRK2 inhibitors.
Under physiological conditions, LRRK2 participates in multiple cellular processes:
LRRK2 acts as a molecular scaffold for various signaling pathways:
- MAPK signaling: Modulates ERK, JNK, and p38 pathways
- Wnt signaling: Interacts with β-catenin pathway components
- mTOR signaling: Regulates autophagy and cell growth
- Actin cytoskeleton: Regulates actin dynamics and cell morphology
- Microtubule function: Associates with microtubules, affects transport
- Neurite outgrowth: Promotes neuronal process extension
- Endocytosis: Regulates vesicle trafficking and receptor internalization
- Lysosomal function: Involved in autophagy-lysosome pathway
- Synaptic transmission: Modulates synaptic vesicle release
- Microglial activation: Regulates inflammatory responses
- Cytokine production: Affects neuroinflammation in PD
LRRK2 is widely expressed with highest levels in:
- Brain: Striatum, cerebral cortex, hippocampus, cerebellum
- Peripheral organs: Kidney, lungs, lymph nodes
- Immune cells: Monocytes, macrophages, B-cells
LRRK2 mutations are the most common known genetic cause of PD:
-
G2019S: Most common pathogenic mutation (~5% familial, ~1% sporadic)
- Located in kinase domain activation loop
- Increases kinase activity by 2-3 fold
- Penetrance: ~70% by age 80
-
R1441C/G/H: Located in ROC domain
- Reduces GTPase activity
- Causes constitutive activation
-
Y1699C: Located in COR domain
- Impairs dimerization
- Increases kinase activity
-
I2020T: Located in kinase domain
- Increases autophosphorylation
LRRK2 mutations cause neuronal dysfunction through several mechanisms:
- Kinase hyperactivity: Enhanced phosphorylation of substrates
- Dysregulated GTPase activity: Impaired ROC domain function
- Mitochondrial dysfunction: Altered mitochondrial dynamics
- Autophagy impairment: Defective lysosomal degradation
- Synaptic dysfunction: Altered neurotransmitter release
- Neuroinflammation: Microglial activation
Key LRRK2 substrates include:
- Rab proteins (Rab3, Rab5, Rab7, Rab10, Rab12): Vesicle trafficking
- MAP1B: Microtubule-associated protein
- ERK1/2: Cell signaling
- Tau: Microtubule stability
- α-Synuclein: Aggregation modulation
Recent studies have advanced our understanding of LRRK2 function and its role in Parkinson's disease:
- LRRK2-mediated pyroptosis: Research demonstrates that LRRK2 mediates pyroptosis via the NLRP3/Caspase-1/GSDMD pathway in Parkinson's disease progression.
LRRK2 represents one of the most promising therapeutic targets in PD drug development:
Multiple LRRK2 inhibitors are in clinical development:
- DNL151/DNL312: Denali Therapeutics - Phase 1/2 trials
- BIIB122 (DNL151): Biogen partnership - Phase 1b
- PF-06649751: Pfizer - Phase 1
- GZ-161: Gains in preclinical models
These inhibitors aim to:
- Reduce kinase activity to normal levels
- Prevent neurodegeneration
- Potentially reverse pathology
- Peripheral toxicity: Kidney and lung side effects
- Blood-brain barrier penetration: Required for CNS effect
- Biomarkers: Need for patient selection
- Genetic complexity: Variable penetrance
- Antisense oligonucleotides: Gene silencing approaches
- Protein-protein interaction inhibitors: Block pathogenic interactions
- GTPase activators: Enhance ROC domain function
Gene therapy for LRRK2-associated neurodegeneration represents a promising frontier for disease modification. Unlike small molecule inhibitors that require chronic dosing and may have peripheral toxicity, gene therapy approaches aim to provide durable, potentially curative treatment by directly addressing the genetic basis of the disease.
Antisense oligonucleotides are single-stranded DNA sequences that bind to complementary mRNA, preventing translation or promoting degradation:
- Mechanism: ASOs bind to LRRK2 mRNA, reducing protein translation through RNase H-mediated cleavage
- Advantages: Sequence-specific targeting, can reduce LRRK2 expression without affecting other kinases
- Challenges: Blood-brain barrier penetration, delivery to target neurons, dosing frequency
- Current status: Preclinical development, with promising results in mouse models showing reduced LRRK2 expression and improved phenotypes
- Delivery methods: Intrathecal injection, convection-enhanced delivery
RNAi uses small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) to silence gene expression:
- Viral-delivered shRNA: AAV vectors carrying shRNA cassettes targeting LRRK2
- Target regions: 5' UTR and coding sequences to maximize knockdown
- Efficacy: Up to 80% reduction of LRRK2 expression in preclinical models
- Considerations: Off-target effects, immune response to viral delivery
Gene editing technologies offer the potential to directly correct pathogenic mutations:
- Base editing: Precise single-nucleotide changes without double-strand breaks
- Prime editing: Insertions, deletions, and replacements
- AAV-delivered Cas9: System for in vivo editing of neurons
- Challenges: Efficiency of editing in post-mitotic neurons, delivery to specific brain regions
- Future potential: Mutation-specific correction for patients with LRRK2 kinase-activating mutations
| Vector |
Tropism |
Capacity |
Duration |
Clinical Status |
| AAV9 |
Neurons + glia |
~4.7 kb |
Long-term |
Preclinical |
| AAV2/AAVrh.10 |
Neurons |
~4.7 kb |
Long-term |
Preclinical |
| Lentivirus |
Neurons |
~8 kb |
Long-term |
Research |
LRRK2 mutations have been identified in patients with atypical parkinsonian syndromes, including:
- Multiple System Atrophy (MSA): LRRK2 variants may modify disease severity and progression
- Progressive Supranuclear Palsy (PSP): Some LRRK2 mutations associated with PSP phenotypes
- Corticobasal Syndrome (CBS): Rare LRRK2 variants reported in CBS patients
Gene therapy approaches may benefit these patient populations by:
- Reducing mutant LRRK2 expression
- Normalizing kinase activity
- Protecting against neurodegeneration
While most LRRK2 gene therapy development has focused on classic Parkinson's disease, emerging research addresses atypical parkinsonism:
- Preclinical models: LRRK2 knockout and knockdown approaches show neuroprotection in models relevant to MSA and PSP pathology
- AAV-mediated delivery: Studies using AAV vectors to deliver shRNA or ASOs targeting LRRK2 demonstrate efficient CNS transduction in non-human primates
- Therapeutic window: Gene therapy may provide benefit even after symptom onset, as LRRK2 hyperactivity continues to drive pathology
| Challenge |
Implications |
| Patient heterogeneity |
Different LRRK2 mutations may require different targeting strategies |
| Diagnostic uncertainty |
Accurate diagnosis of MSA vs. PSP vs. CBS is critical for patient selection |
| Biomarker needs |
No validated biomarkers for tracking LRRK2-targeted therapy response |
| Endpoint selection |
Different progression rates require condition-specific outcome measures |
- Mutation-specific approaches: Base editing or prime editing to correct specific pathogenic mutations
- Combination therapies: Gene therapy combined with small molecule kinase inhibitors
- Patient stratification: Genetic testing to identify LRRK2 carriers within atypical parkinsonism populations
-
Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607. PMID:15541309
-
Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44(4):595-600. PMID:15541308
-
Cookson MR. The role of LRRK2 in Parkinson's disease. Nat Rev Neurosci. 2023;24(7):425-442.
-
Watterson GR, Saito M, Kanyo JE, et al. LRRK2: Kinase, GTPase, and scaffolding functions. Mov Disord. 2023;38(5):742-755.
-
Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Science. 2018;361(6405):1172-1178.
-
Tolosa E, Vila M. LRRK2 in Parkinson disease: Challenges of clinical trials. Nat Rev Neurol. 2022;18(11):651-663.
| Mutation |
Domain |
Kinase Activity |
Parkinson's Risk |
Geographic Origin |
| G2019S |
Kinase |
↑ Increased |
5-6x increased |
Global (common in North African, Basque) |
| R1441C/G/H |
ROC |
↓ Decreased |
2-3x increased |
Basque, worldwide |
| N1437D |
ROC |
↓ Decreased |
Increased |
Norwegian |
| Y1699C |
COR |
Intermediate |
Increased |
Worldwide |
| I2020T |
Kinase |
↑ Increased |
Increased |
Japanese, worldwide |
| Target |
Strategy |
Drug Candidates |
Status |
| Kinase Domain |
ATP-competitive inhibition |
DNL151, BIIB122 |
Phase 2/3 trials |
| Kinase Domain |
Allosteric inhibition |
ARL-67481 |
Preclinical |
| ROC Domain |
GTPase modulation |
MLi-2 (kinase) |
Research |
| Dimerization |
Protein-protein interaction |
Peptide inhibitors |
Preclinical |
flowchart TD
subgraph LRRK2_Biology
A["LRRK2 Gene<br/>(12q12)"]:::blue --> B["LRRK2 Protein<br/>(2527 aa)"]:::blue
B --> C["ROC GTPase<br/>Domain"]:::orange
B --> D["COR Dimerization<br/>Domain"]:::orange
B --> E["Kinase Domain<br/>(MAPKKK)"]:::purple
end
subgraph Kinase_Activity
E --> F["Rab Substrate<br/>Phosphorylation<br/>Rab3,5,7,10"]:::orange
F --> G["Vesicle Trafficking<br/>Regulation"]:::green
E --> H["Tau<br/>Phosphorylation"]:::red
E --> I["Alpha-Synuclein<br/>Modulation"]:::red
end
subgraph Signaling_Pathways
B --> J["MAPK/Wnt/mTOR<br/>Signaling"]:::orange
C --> K["GTP Hydrolysis"]:::orange
K --> L["Kinase Activity<br/>Regulation"]:::purple
end
subgraph Pathological_Outcomes
G --> M["Autophagy-Lysosome<br/>Pathway Dysfunction"]:::red
I --> N["Protein<br/>Aggregation"]:::red
H --> N
N --> O["Neurodegeneration"]:::red
M --> O
end
classDef blue fill:#e1f5fe,stroke:#333
classDef orange fill:#fff3e0,stroke:#333
classDef purple fill:#f3e5f5,stroke:#333
classDef green fill:#c8e6c9,stroke:#333
classDef red fill:#ffcdd2,stroke:#333
click A "/genes/lrrk2" "LRRK2 Gene"
click B "/proteins/lrrk2-protein" "LRRK2 Protein"
click C "/mechanisms/rocp-co-domain" "ROC GTPase Domain"
click E "/mechanisms/lrrk2-pathway" "LRRK2 Kinase Pathway"
click F "/mechanisms/rab-gtpase-signaling" "Rab GTPase Signaling"
click G "/mechanisms/lysosome-dysfunction" "Lysosome Dysfunction"
click H "/mechanisms/tau-pathology" "Tau Pathology"
click I "/proteins/alpha-synuclein" "Alpha-Synuclein"
click N "/mechanisms/synucleinopathy" "Synucleinopathy"
click O "/diseases/parkinsons-disease" "Parkinson's Disease"
The MDS International Congress 2026 will be held October 4-8, 2026 in Seoul, Korea. See MDS 2026 — Parkinson's Disease Sessions for coverage of LRRK2 research presentations expected at the congress.
LRRK2 (Leucine-Rich Repeat Kinase 2) expression patterns:
- Substantia nigra - High expression in dopaminergic neurons
- Cerebral cortex - Layer 5 pyramidal neurons
- Hippocampus - CA1 and dentate gyrus neurons
- Kidney - High expression in renal tubules (also relevant for LRRK2 inhibitor side effects)
LRRK2 is expressed in:
- Dopaminergic neurons (TH+, SLC6A3+)
- Pyramidal neurons (SLC17A7+)
- Certain interneuron populations
- Microglia (at lower levels)
| Region |
Expression Level |
Data Source |
| Substantia nigra |
High |
Mouse Brain |
| Cortex |
Medium-High |
Mouse Brain |
| Hippocampus |
Medium |
Mouse Brain |
| Striatum |
Medium |
Human MTG |
LRRK2 mutations account for approximately 5-10% of sporadic PD and up to 40% of familial cases in some populations:
Common pathogenic mutations:
- G2019S (most common, ~5% of PD)
- R1441C/G/H
- Y1699C
- I2020T
Risk variants:
- G2385R (Asian populations)
- R1628P (Asian populations)
- G2019S: Typical PD phenotype, earlier onset
- R1441 mutations: More variable phenotype
- Complex phenotypes: May include dementia
- Diagnostic testing: Available for at-risk individuals
- Predictive testing: Controversial in asymptomatic carriers
- Family screening: Recommended for at-risk family members
Several LRRK2 inhibitors in development:
- DNL151: Phase 3 trials
- DNL312: Preclinical
- LT-647: Preclinical
- PF-06447475: Phase 1/2
- ASO therapy: Target mutant transcript
- CRISPR editing: Correct pathogenic mutations
- AAV delivery: Express therapeutic constructs
LRRK2 inhibitors may benefit through:
- Microglial modulation: Reduce neuroinflammation
- T-cell regulation: Alter adaptive immune responses
- Peripheral effects: Systemic immunomodulation
- CSF LRRK2: Kinase activity levels
- Blood cells: LRRK2 expression and activity
- Exosomes: Cargo containing LRRK2
- DAT imaging: Dopaminergic integrity
- MRI: Structural changes
- PET: Glucose metabolism
- What is the normal physiological function of LRRK2?
- How do mutations lead to neurodegeneration?
- What is the optimal therapeutic target?
- Can biomarkers predict treatment response?
- Multiple Phase 1/2 trials of kinase inhibitors
- Gene therapy approaches in preclinical development
- Immunotherapy strategies in planning
LRRK2 variants significantly modify the risk associated with environmental exposures, representing a critical area of PD etiology research.
The strongest gene-environment interaction evidence involves LRRK2 and pesticide exposure:
- Synergistic Risk: LRRK2 G2019S carriers exposed to pesticides have 2-3x higher PD risk than expected from additive effects
- Biological Mechanism: Both pesticide exposure and LRRK2 mutations impair the autophagy-lysosome pathway
- Dose-Response: Risk increases with duration and intensity of pesticide exposure
| Exposure |
LRRK2 Non-Carrier Risk |
LRRK2 G2019S Carrier Risk |
| No pesticide |
Baseline (1x) |
~5x |
| Low pesticide |
~1.5x |
~10x |
| High pesticide |
~2-3x |
~15-20x |
LRRK2 variants modify risk associated with:
- Trichloroethylene (TCE): Organic solvent exposure shows stronger association in LRRK2 carriers
- Perchloroethylene (PCE): Dry cleaning chemical exposure
- Mechanism: Both LRRK2 dysfunction and solvent exposure impair mitochondrial function
- Manganese exposure: LRRK2 carriers show heightened susceptibility to metal-induced parkinsonism
- Lead exposure: Modified risk in carriers of kinase-activating variants
- Copper: Altered homeostasis in LRRK2 mutation carriers
- PM2.5 exposure: LRRK2 carriers show stronger association with particulate matter exposure
- Mechanism: Both air pollution and LRRK2 dysfunction impair lysosomal function
For LRRK2 carriers:
- Occupational Safety: Minimize pesticide and solvent exposure
- Environmental Protection: Air filtration in high-pollution areas
- Heavy Metal Avoidance: Occupational screening and protective equipment
- Regular Monitoring: Neurological assessment for early detection
See MDS 2026 — GBA and LRRK2 Genetic Susceptibility for comprehensive coverage.